Great time for pain research: Exclusive interview with Neil Singla of Lotus Clinical Research, Llc

On Apr 2, 2018

Ahead of 18th annual Pain Therapeutics Conference (London, 21 – 22 May) SMi Group recently have caught up with Neil Singla, Founder & Chief Scientific Officer at Lotus Clinical Research, Llc to talk about industry and his vision on challenges and opportunities that lay ahead.

Q. Where do you see the greatest opportunities for analgesic therapeutics leaders?

A. We are in a great time for pain research. I’m seeing more great minds and more companies entering the field than at any other time in my 17-year history running Lotus. In light of the opioid crisis, the societal need for new therapies is so great that it’s created increased interest in the field from industry, academia and clinicians. I think researchers who develop an NCE with a novel mechanism of action in pain are in a position to change the world for the better, as are researchers who refine existing drugs to reduce potential harm.

This is a snap-shot of the Q&A and full transcript can be found at http://www.pain-therapeutics.co.uk/pharmajourn

With preparations well underway for Pain Therapeutics Conference, organizers are reminding to make a note in the work schedule to attend this event which will offer an unparalleled expertise and insight into the analgesics medicine world!

Neil will also be delivering a Keynote Address on Abdominoplasty as a novel analgesic model for acute soft tissue pain on the Day 1 of the Pain Therapeutics Conference

An elite speaker line-up is bound to inspire attendees through the exploration of innovative approaches and novel targets in analgesic medicine:

explore the possibilities of DNA-based, disease modifying treatments for painful diabetic neuropathy with ViroMed;
overcome the challenges of patient recruitment and the placebo response with Novartis;
learn how AstraZeneca and Eli Lilly are targeting ion channels to reduce pain.

SMi Group also run Interactive Workshops on 23rd May alongside the Main event:

A: How Should the Likely Future Pain Therapeutic Landscape Inform Current Drug Development? By Prescient Healthcare Group
B: Clinical, Regulatory and Market Access Aspects in the Development of Medicinal Products intended for the Treatment of Pain in Europe and USA. By Pharma Design Ltd.

For further information visit http://www.pain-therapeutics.co.uk/pharmajourn

CONTACT:
+44 (0)20 7827 6000
ldurneva@smi-online.co.uk
Twitter – @SMIpharm & #smipaintherapeutics
LinkedIn – SMi Pharma

————————————————————————————————————-

Pain Therapeutics Conference | 21 – 22 May 2018 | London, UK
http://www.pain-therapeutics.co.uk/pharmajourn

————————————————————————————————————-